TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 3 years of age or older~* Patients must be planning to undergo standard of care treatment with surgery and radiation therapy.~* Patients must have malignant glioma or recurrent ependymoma~* Tumor must be accessible for injection and must not be located in the brainstem or deep midbrain~* Performance Score: Karnofsky ≥60% if \>10y/o, Lansky ≥60 if ≤10y/o~* Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ≥ 1000/µl, platelet count ≥ 100,000/µl (transfusion independent) and hemoglobin ≥ 8.0 gm/dL~* Renal Function: Patients must have serum creatinine ≤ 1.5 times upper limit of institutional normal for age and/or GFR ≥ 70 mL/min/1.73 m2.~* Hepatic Function: Bilirubin ≤ 1.5 times institutional normal; SGPT (ALT) \< 3 times institutional normal~* Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked prior to enrollment and clinically significant abnormalities corrected prior to surgery/AdV-tk injection~* Patients with seizure disorder may be enrolled if well controlled~* Signed informed consent according to institutional guidelines must be obtained~Exclusion Criteria:~* Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection~* Patients on immunosuppressive drugs (with exception of corticosteroid)~* Known history of HIV or underlying immunodeficiency~* Patients with acute infections (viral, bacterial or fungal infections requiring therapy)~* Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy~* Other serious co-morbid illness or compromised organ function~* No other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- AdV-tk (Type: EXPERIMENTAL): AdV-tk + valacyclovir in combination with standard of care radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Applicable disease and eligible for myeloablative SCT~* Patients must have two partially HLA-matched CBUs~* Back-up stem cell source~* Adequate Karnofsky Performance score or Lansky Play-Performance scale~* Sufficient physiological reserves~* Signed written informed consent~Exclusion Criteria:~* HLA-matched related donor able to donate~* Prior allogeneic HSCT~* Lymphoma patients with progressive disease~* Other active malignancy~* Human immunodeficiency virus (HIV) infection~* Active or uncontrolled infection~* Active/symptoms of central nervous system (CNS) disease~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NiCord (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination~* BMI 25-45 kg/m\^2~* HbA1c between 7.5 % and 12.0 %, inclusive~Exclusion Criteria:~* Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening~* Patients previously treated with AC2993~* Patients presently treated with insulin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AC2993 (Type: EXPERIMENTAL): 5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Environmental Enteropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1-3 years of age~* Lives in study villages~* Will not move in next 6 months~* Caregiver willing to give intervention daily for 6 months~Exclusion Criteria:~* Unable to drink 20 mL of sugar water~* Demonstrating evidence of severe acute malnutrition, WHZ \< or = -3, presence of bi-pedal pitting edema~* Apparent need for acute medical treatment for an illness or injury~* Caregiver refusal to participate and return for 3 and 6 month follow-ups

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 3 Years
- Healthy Volunteers: t

Study Arms:
- Fish oil and Micronutrient Supplementation (Type: EXPERIMENTAL): None
- Micronutrient Supplementation (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Steroids and the Nasal Ocular Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~1. Males and females between 18 and 45 years of age.~2. History of grass and/or ragweed allergic rhinitis.~3. Positive skin test to grass and/or ragweed antigen.~4. Positive response to screening nasal challenge.~Exclusion Criteria~1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~2. Pregnant or lactating women.~3. Upper respiratory infection within 14 days of study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Simplified Patient-Centered Educational Tool for Improved Hearing-Aid Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Participants will be Veterans who are receiving hearing aids from the Audiology Clinic at the VA Portland Health Care System and who have had no prior experience using hearing aids. To be included in the study, participants will:~* Be approved and have plans to get bilateral hearing aid fitting at the VA Portland Health Care System .~* Be able to read and converse in English.~Exclusion Criteria:~* Be younger than 50 years or older than 89 years of age.~* Have a documented diagnosis of neurological, cognitive, visual, or other mental disorder, such as Alzheimer's disease, schizophrenia, current alcohol or substance abuse, as determined by chart review that would interfere with study completion.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Standard of care (SoC) (Type: ACTIVE_COMPARATOR): standard of care hearing-aid orientation as provided by clinical audiologist
- SoC plus hearing-aid informational guide (Type: EXPERIMENTAL): standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
- SoC plus hearing aid DVD (Type: EXPERIMENTAL): SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
- Soc plus teach-back technique (Type: EXPERIMENTAL): standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin and Analgesia After Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II~Exclusion Criteria:~* Renal or hepatic insufficiency~* Alcohol or drugs abuse~* History of chronic pain or daily intake of analgesics~* Uncontrolled medical disease (hypertension, diabetes) and cardiovascular problems. Psychiatric disorders~* Inability of patients to use PCA pump~* History of intake of non-steroidal anti-inflammatory drugs the last 24 hours before surgery,use of drainage after the surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
- Placebo (Type: PLACEBO_COMPARATOR): Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Only patients who are medically suitable for corneal refractive surgery can be included in the study.~* Subjects should be 21 years of age or older~* Eyes with high myopia spherical equivalent between -9.00 D up to -14.00 D, with cylinder up to 7.00 D~* The corrected distance visual acuity will be 20/40 or better in each eye pre-operatively~* Calculated sub-lenticule thickness (SLT) ≥220 µm~* Calculated total uncut stromal thickness (TUST) ≥300 µm~* Contact lens wearers must stop wearing their contact lenses at least four weeks per decade of wear before baseline measurements in case of hard contact lenses and one week before baseline measurements in case of soft contact lenses.~* Patient will be able to understand the patient information and willing to sign an informed consent~* Patient will be willing to comply with all follow-up visits and the respective examinations as specified in the flow-chart~Exclusion Criteria:~* Previous intraocular or corneal surgery of any kind on the eye being treated~* Patient not being able to lie flat in a horizontal position~* Patient not being able to tolerate local or topical anesthesia~* Autoimmune diseases~* Sicca syndrome, dry eye~* Herpes viral (herpes simplex) infections~* Herpes zoster~* Diabetes~* Pregnant or nursing women (or who are planning pregnancy during the study)~* Patients with a weight of \> 135 kg~* Any residual, recurrent or acute ocular disease or abnormality of the eye, e.g.~  * Cataract~ * Suspected glaucoma or an intraocular pressure \> 21 mm of Hg~ * Corneal disease~ * Corneal thinning disorder, e.g. keratoconus,~ * Pellucid marginal corneal degeneration~ * Dystrophy of the basal membrane~ * Corneal oedema~ * Exudative macular degeneration~ * Infection~* Any residual, recurrent, or active abnormality of the cornea to be treated, e.g.~  * Existing corneal implant~ * Corneal lesion~ * Unstable refraction~ * Connective tissue disease~ * Dry eye

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Small incision lenticule extraction (Type: EXPERIMENTAL): Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of major depression, recurrent, severe without psychotic symptoms according to criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Must be diagnosed with Treatment resistant depression.~18 years old and up Patients had a clinically meaningful response to a course of IV racemic ketamine~Exclusion Criteria:~Active substance abuse, psychosis, significant medical comorbidities, or axis II diagnosis that would interfere with the reliability of outcome measures or response to pharmacotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment resistant depressed outpatients (Type: None): Subjects had a clinically meaningful response to IV racemic ketamine and remained on other psychotropic medications during treatment with both IV ketamine and IN esketamine. Concomitant medication classes included CNS stimulants (n = 7), atypical antipsychotics (n = 6), selective serotonin reuptake inhibitors (n = 5), serotonin/norepinephrine reuptake inhibitors (n = 4), anticonvulsants (n = 3), antipsychotics (n = 3), mood stabilizers (n = 3), benzodiazepines (n = 2), norepinephrine/dopamine reuptake inhibitors (n = 2), alpha 2 antagonists (n=1), and sedative hypnotics (n = 1). Two patients (20%) previously underwent ECT with partial but transient relief from depressive symptoms, two (20%) failed TMS, and no patients reported any period of greater than 50% improvement during their current depressive episode prior to ketamine treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a diagnosis of type 2 diabetes mellitus~* patients with hypertension (seated office SBP of \>=130 mmHg and \<160 mmHg and seated office DBP of \>= 70 mmHg at screening and at Week -2~* patients on stable doses of 1 to 3 anti-hypertensive agents for at least 5 weeks before screening~* patients on stable doses of 1 to 3 oral anti-hyperglycemic agents which must include metformin, for at least 8 weeks before screening~Exclusion Criteria:~* a history of diabetic ketoacidosis~* type 1 diabetes mellitus (T1DM)~* pancreas or beta-cell transplantation~* fasting C-peptide \<0.70 ng/mL (0.23 nmol/L)~* body mass index \<30 kg/m2~* has ongoing, inadequately controlled thyroid disorder~* has a history of cardio-renal disease that required treatment with immunosuppressive therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving maintenance hemodialysis or continuous ambulatory peritoneal dialysis, and dialysis vintage more than 3 months~* Patients aged between 18 and 80 years older~* VitC \< 4ug/ml and hsCRP \> 3mg/L~* for HD patients, Kt/V \> 1.2 per session, at least 3 sessions per week, 4 hours per session~* for PD patients, Kt/V \> 1.7 per week~* age and gender matched health control~Exclusion Criteria:~* Active autoimmune disease, malignancy, hepatitis~* Positive HIV serology~* Any kind of acute infection within one month, chronic infection~* Currently using steroids or immune-suppressants~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- arm1, vitamin C treated first (Type: OTHER): Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
- Arm 2 control first (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MSB11022 in Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis based on 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria~* At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline~* Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Evidence of untreated or inadequately treated latent or active Tuberculosis~* Evidence of uncontrolled, clinically significant diseases~* Any second disease-modifying antirheumatic drugs must be washed out prior to the first study dose~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MSB11022 (Type: EXPERIMENTAL): None
- EU-Humira (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants had given written informed consent to participate in the study in accordance with local regulations.~* Adult participants 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent.~* Participants were being treated with insulin or insulin analog delivered. via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).~* Willing and able to perform self-monitored blood glucose (SMBG) and complete the study diary as required per protocol.~* At the Screening Visit, A1C must be between 7.0% to 11.0%.~* Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test .~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to randomization.~* Chronic systemic corticosteroid use.~* Type 2 diabetes mellitus (T2D), or severely uncontrolled T1D as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
- Sotagliflozin 200 milligrams (mg) (Type: EXPERIMENTAL): Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete